Laboratoires Théa

Executive Summary

Laboratoires Théa is a French private pharmaceutical company exclusively dedicated to ophthalmology, founded in 1994 and headquartered in Clermont-Ferrand. The company develops, manufactures, and markets a comprehensive range of eye care products, from prescription drugs to over-the-counter solutions, with a strong emphasis on preservative-free formulations. Operating globally, Théa focuses on innovation, sustainability, and knowledge sharing within the eye care community. With a robust pipeline targeting dry eye, glaucoma, and inflammation, the company is advancing several products through late-stage clinical trials. Its preservative-free portfolio differentiates it in a competitive market, addressing patient compliance and safety concerns. As a privately held entity, Théa maintains strategic flexibility and has established a strong presence in Europe, the Middle East, and Asia. The company's commitment to R&D and partnerships positions it for sustained growth. Key upcoming catalysts include the anticipated launch of a new preservative-free dry eye treatment in Europe, Phase 3 data readouts for a novel glaucoma combination therapy, and potential expansion into the Japanese market through strategic alliances.

Upcoming Catalysts (preview)

• Q3 2026Launch of new preservative-free dry eye treatment in Europe75% success
• Q4 2026Phase 3 data readout for novel glaucoma combination therapy65% success
• 2026Expansion into Japanese market via partnership or licensing deal70% success